The Walensky Laboratory

Loren D. Walensky, MD PhD

Principal Investigator

Loren D. Walensky, MD, PhD is a Professor of Pediatrics at Harvard Medical School, Principal Investigator and Attending Physician in the Department of Pediatric Hematology/Oncology at the Dana-Farber Cancer Institute/Children’s Hospital Boston, and Director of the Harvard/MIT MD-PhD Program. He serves as an adjunct faculty member in the Department of Cancer Biology at Dana-Farber and is affiliated with the graduate programs in Biological and Biomedical Sciences, and Chemical Biology at Harvard Medical School.

Dr. Walensky graduated as valedictorian from Princeton University in 1990, majoring in Chemistry (laboratory of Edward Taylor, PhD) and receiving a Certificate in Science Policy from the Woodrow Wilson School of Public and International Affairs. He went on to receive his MD and PhD (laboratory of Solomon Snyder, MD) from the Johns Hopkins University School of Medicine in 1997. Dr. Walensky trained in pediatrics at the Boston Combined Residency Program in Pediatrics. He completed a fellowship in pediatric hematology/oncology at the Dana-Farber Cancer Institute/Children’s Hospital Boston, where his postdoctoral research in cancer chemical biology was jointly mentored by Gregory Verdine, PhD of Harvard University and the late Stanley Korsmeyer, MD of Dana-Farber. Dr. Walensky joined the Dana-Farber and Harvard Medical School faculty as Instructor of Pediatrics in 2003, founded his independent research laboratory in 2006, and was promoted to Associate Professor in 2011. Dr. Walensky is the recipient of numerous prestigious awards including a Stand Up to Cancer Innovative Research Grant, an NIH Director’s Transformative RO1 Award, a Burroughs Wellcome Career Award in the Biomedical Sciences, a Leukemia and Lymphoma Society Scholar Award, a Harvard Medical School Young Mentor Award, and most recently, the Dana-Farber Cancer Institute’s Morse Award for Research Excellence, the Samuel Rosenthal Prize for Excellence in Academic Pediatrics, the E. Mead Johnson Award for Pediatric Research, and an NCI Outstanding Investigator R35 Award.

Dr. Walensky’s work contributed to the founding of Aileron Therapeutics in Cambridge, MA. The company’s first-in-class stapled peptide drug to reactivate p53 in cancer, developed based on Dr. Walensky’s research, is currently being evaluated in Phase I clinical trials.